Jeannie Lee, MD, PhD - 2021 World Medical Innovation Forum
May 2–4, 2022
Jeannie Lee
This speaker appears at this event:

Jeannie Lee, MD, PhD

Molecular Biologist, MGH

Professor of Genetics, HMS

Jeannie T. Lee, MD is a Professor of Genetics at Harvard Medical School and the Massachusetts General Hospital. Dr. Lee specializes in the study of epigenetic regulation by long noncoding RNAs and uses X-chromosome inactivation as a model system. She is a Member of the National Academy of Sciences, a 2018 Harrington Rare Disease Scholar of the Harrington Discovery Institute, the 2016 recipient of the Lurie Prize from the Foundation for the National Institutes of Health, a 2016 awardee of the Centennial Prize from the Genetics Society of America, the 2010 recipient of the Molecular Biology Prize from the National Academy of Sciences, U.S.A, and a Fellow of the American Association for the Advancement of Science.

Dr. Lee was also named a Distinguished Graduate of the University of Pennsylvania School of Medicine and was an Investigator of the Howard Hughes Medical Institute. From 2013-2018, she co-launched the Epigenetics Initiative at Harvard Medical School and served as its Co-Director. Serving on the Board of Directors of the Genetics Society of America (GSA), Dr. Lee spearheaded the TAGC (The All-Genetics) Conference in 2016. As GSA’s President, Dr. Lee established a Strategic Plan and a Development strategy for the society in 2018.

She received her A.B. in Biochemistry and Molecular Biology from Harvard University and obtained M.D.-Ph.D degrees from the University of Pennsylvania School of Medicine. Dr. Lee then carried out postdoctoral work at the Whitehead Institute & MIT and became Chief Resident of Clinical Pathology at the Massachusetts General Hospital prior to joining the Faculty at Harvard Medical School. As a new investigator, she received the Basil O’Connor Scholar Award from the March of Dimes and the Pew Scholars Award. Growing knowledge of X-inactivation mechanisms and RNA biology is currently being translated to treat various human diseases, including Rett, Fragile X, and CDKL5 Syndromes. As a champion of translational science, she played a major role in the founding of Translate Bio and Fulcrum Therapeutics with technology from the lab. ​

the Future of Medicine and AI

May 11–13, 2020 | Boston, MA